Early-Window Hormone Replacement Therapy
A hormone replacement regimen combining transdermal estrogen, oral progesterone, and transdermal testosterone, initiated within 3–5 years of menopause onset.
Assembled by Cited from Steven Gundry's recorded recommendations across multiple sources. It is not an ordered program and was not created or endorsed by them — it's our grouping of what they've said on the record.
Components
3-
In a protocol
As part of hormone replacement, transdermal estrogen started within 3–5 years of menopause onset is probably protective against heart disease and bone loss.
“transdermal estrogen, a oral progesterone, and a transdermal testosterone
TD▶ 13:10DosageStarted within 3–5 years of beginning menopause; transdermal routeCaveatsStarting outside this window increases risk of breast/ovarian cancer, bone loss, or heart disease.CertaintyhedgedrecommendationTransdermal estrogen -
In a protocol
Oral progesterone is part of the HRT protocol Gundry supports when begun within 3–5 years of menopause.
“oral progesterone
TD▶ 13:10DosageOral route; begin within 3–5 years of menopauseCaveatsPlaying 'Russian roulette' if begun after the early window.CertaintyhedgedrecommendationOral progesterone -
In a protocol
Transdermal testosterone can be part of early-window HRT for women, but keep levels within normal female range to avoid cardiovascular risk.
“transdermal testosterone, if it started within three to five years
TD▶ 13:10DosageTransdermal; do not exceed normal female rangeCaveatsExcess testosterone in women promotes coronary artery disease.Certaintyhedgedmild cautionTransdermal testosterone, kept within normal female range